MADRID – The Spanish pharmaceutical company Hipra Human Health is assured of the sale of 250 million doses of its protein vaccine against the coronavirus to Brussels. Consequently, the European Commission signed the purchase contract this Tuesday.
A total of 14 Member States will participate in this joint purchase. However, the value of which has not been disclosed by Brussels. Moreover, under this agreement, 250 million vials of this Spanish protein vaccine will be supplied. These can be used as a booster dose for previously immunised people over 16 years of age.
See also: Corona vaccine Hipra from Spain soon in the European vaccination program
Given the increase in COVID infections in Europe, “we must ensure maximum preparedness as we approach the autumn and winter months,” Health Commissioner Stella Kyriakides said in a statement.
Ensures approximately 4,2 billion doses
This vaccine is currently under evaluation by the European Medicines Agency (EMA), so if the marketing authorisation is obtained, participating countries will be able to purchase the vaccine through this current contract.
The joint vaccine purchase agreement with Hipra complements contracts previously signed with the following;
- AstraZeneca
- Sanofi-GSK
- Janssen Pharmaceutica
- BioNTech-Pfizer
- Moderna
- Novavax
- Valneva
Consequently, securing some 4.2 billion doses for the EU market as part of the COVID vaccination strategy.
Participating countries can decide to donate the vaccines to low- and middle-income countries or to forward them to other European countries.
